ClickHouse Raises $350 Million Series C to Power Analytics for the AI Era
29.5.2025 17:30:00 EEST | Business Wire | Press release
ClickHouse, Inc., a leader in real-time analytics, data warehousing, observability, and AI/ML, today announced it has raised $350 million in Series C financing. The round was led by Khosla Ventures, with participation from new investors BOND, IVP, Battery Ventures, and Bessemer Venture Partners, as well as existing investors including Index Ventures, Lightspeed, GIC, Benchmark, Coatue, FirstMark, and Nebius. Today’s round follows earlier investments of over $300 million, bringing total funding to over $650 million.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529254399/en/
The ClickHouse Founders - Aaron Katz, Yury Izrailevsky, Alexey Milovidov
This combined funding will be used to scale product development, support global expansion, and deepen partnerships with customers and technology providers building the next wave of AI-native applications. In addition to this financing, ClickHouse has secured a $100 million credit facility led by Stifel and Goldman Sachs.
The momentum behind ClickHouse is accelerating: the company grew over 300% during the past year and now serves over 2,000 customers across a range of industries from fintech and transportation to consumer and healthcare. New customers include Anthropic, Tesla, and Argentina’s Mercado Libre, among others. They join companies such as Sony, Meta, Memorial Sloan Kettering, Lyft, and Instacart, as well as AI innovators Sierra, Poolside, Weights & Bases, Langchain, and more.
Today’s announcement was made at ClickHouse’s inaugural user conference, showcasing how enterprises are building data products to meet the demands of the agentic era.
“As AI agents proliferate across data-driven applications, observability, data infrastructure, and beyond, the demand for agent-facing databases like ClickHouse has reached an inflection point. The future of analytics isn’t just dashboards. It’s intelligent agents that interpret data, trigger workflows, and power real-time decisions,” said Aaron Katz, CEO of ClickHouse. “But AI is just one driver. We designed and built ClickHouse from day one to support a broad spectrum of real-time data applications across industries, and our momentum reflects that enterprises are hungry for a platform that can keep up with their scaling ambitions.”
“We invested in ClickHouse because they’re solving one of the most important infrastructure challenges of this era of AI and agents: enabling real-time data platforms that can support both traditional analytics and the growing demands of AI-native workloads,” said Ethan Choi, Partner at Khosla Ventures. “As AI reshapes every industry, the ability to deliver fast, scalable, and cost-efficient analytics is becoming foundational, ClickHouse is poised to become the default engine for next-generation intelligent data products.”
The Next Frontier: Real-Time Analytics for Agentic Workloads
The market traction around ClickHouse is rooted in a fundamental shift: enterprises are no longer just building dashboards or batch reports—they are building real-time, intelligent data platforms that must serve both human and AI agents. Since AI agents can generate queries much faster and at a higher rate than human analysts, agent-facing databases must support low-latency, interactive analytical queries at an increasingly high throughput.
ClickHouse was designed from the ground up to meet this demand. Its high-performance, columnar storage engine enables interactive, analytical queries across massive datasets with minimal latency—perfect for powering AI and ML applications, real-time analytics, cloud data warehousing, and observability workloads.
Built for Speed at Scale: High-Performance Analytics Across Industries
Traditional databases and warehouses are struggling to keep up with this demand. Transactional databases don’t scale for analytical workloads. Meanwhile, traditional data warehouses are optimized for internal, batch-heavy use cases with limited concurrency and slow performance. Finally, search-oriented technologies become prohibitively expensive for structured analytics—using 10x more in storage and compute and limiting the practical range of applications due to cost.
By contrast, ClickHouse offers a purpose-built solution that bridges the gap—combining high-performance analytics with the scalability and concurrency that today’s intelligent, data-driven applications require.
About ClickHouse
ClickHouse is a fast, open-source columnar database management system built for real-time data processing and analytics at scale. Engineered for high performance, ClickHouse Cloud delivers exceptional query speed and concurrency, making it ideal for applications that demand instant insight from massive volumes of data. As AI agents become increasingly embedded in software and are generating far more frequent and complex queries, ClickHouse brings a high-throughput, low-latency engine, purpose-built to meet this challenge. Trusted by leading companies like Sony, Tesla, Anthropic, Memorial Sloan Kettering, Lyft, and Instacart, ClickHouse helps teams unlock insights and drive smarter decisions with a scalable, efficient, and modern data platform. For more information, visit clickhouse.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250529254399/en/
Contacts
Tanya Bragin
VP, Product & Marketing
press@clickhouse.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom